# Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetic, and Food Effects of ARD-885 Film-coated Tablets in Healthy Chinese Subjects and Patients With Rheumatoid Arthritis

> **NCT07266207** · PHASE1 · COMPLETED · sponsor: **Artivila (Shenzhen) Innovation Center, Ltd** · enrollment: 94 (actual)

## Conditions studied

- Rheumatoid Arthritis (RA)

## Interventions

- **DRUG:** ARD-885 Tablets
- **DRUG:** ARD-885 Placebo Tablet

## Key facts

- **NCT ID:** NCT07266207
- **Lead sponsor:** Artivila (Shenzhen) Innovation Center, Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-12-16
- **Primary completion:** 2025-08-14
- **Final completion:** 2025-08-18
- **Target enrollment:** 94 (ACTUAL)
- **Last updated:** 2025-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07266207

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07266207, "Phase I Study to Evaluate Safety, Tolerability, Pharmacokinetic, and Food Effects of ARD-885 Film-coated Tablets in Healthy Chinese Subjects and Patients With Rheumatoid Arthritis". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT07266207. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*